Slide 1: ARV-471: Phase 2 VERITAC Trial Results
ARV-471: Phase 2 VERITAC Trial Results November 22, 2022 Exhibit 99.1
Slide 2: Safe harbor and forward-looking statements
Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the including statements regarding the potent
Slide 3: Agenda
Agenda 3 Topic Participant Introduction John G. Houston, Ph.D. President and Chief Executive Officer, Arvinas ARV-471: VERITAC Clinical Data Update Ron Peck, M.D. Chief Medical Officer, Arvinas Conclusions John G. Houston, Ph.D. President and Chief Executive Officer, Arvinas Includes: Chris Boshoff,
Slide 4: ARV-471: Potential best-in-class estrogen receptor-targeting therapy
ARV-471: Potential best-in-class estrogen receptor- targeting therapy 4 Continued signals of efficacy across the Phase 1/2 trial in a patient population with 100% pretreatment with CDK4/6 inhibitors • To our knowledge, this is the most heavily pre-treated patient population evaluated with an ER-targ
Slide 5: ARV-471: Potential to be the endocrine backbone of choice for ER+/HER2- breast cancer
ARV-471: Potential to be the endocrine backbone of choice for ER+/HER2- breast cancer treatment 5 Potential Future US ER+/HER2- Breast Cancer Treatment Paradigm with ARV-471 Adjuvant (Post-Surgical) Breast Cancer (~160K)* Metastatic Breast Cancer (~50K*) Second/Third LineFirst Line Endocrine Backbon
Slide 6: Studies with SERDs or ARV-471 Include a Wide Range of Prior Therapies
Studies with SERDs or ARV-471 Include a Wide Range of Prior Therapies VERITAC has most prior therapies among key studies PALOMA-31 Phase 3 study of palbociclib plus fulvestrant vs placebo plus fulvestrant (N=521) 0 0 34%‡ acelERA2 Phase 2 study of giredestrant vs SOC† (N=303) 42%* 19%* 32% SERENA-23
Slide 7: ARV-471: VERITAC Phase 2 Detailed Results
7 Ron Peck, M.D. Chief Medical Officer, Arvinas ARV-471: VERITAC Phase 2 Detailed Results
Slide 8: Phase 2 (VERITAC) Cohort Expansion Design
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 8 aEnrollment in the 200-mg QD cohort began before enrollment i
Slide 9: Patient Baseline Characteristics (VERITAC)
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. Patient Baseline Characteristics (VERITAC) 9 aBaseline ECOG PS
Slide 10: Primary Endpoint: Clinical Benefit Rate (VERITAC)
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 10 aRate of confirmed complete response or partial response or
Slide 11: Tumor Response (VERITAC)
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 11 aIncludes patients with measurable disease (n=44); 1 patient
Slide 12: Progression-Free Survival (VERITAC)
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 100 80 60 40 20 0 Progression-Free Survivala (VERITAC) 12 aLimi
Slide 13: ER Degradation With 200 mg QD ARV-471
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. ER Degradationa With 200 mg QD ARV-471 (Phase 1/VERITAC) 13 aER
Slide 14: Treatment-Emergent Adverse Event Summary (VERITAC)
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. Treatment-Emergent Adverse Event Summary (VERITAC) 14 aAcute re
Slide 15: Treatment-Related Adverse Events by Grade
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 200 mg QD (n=35) 500 mg QD (n=36) Total (N=71) n (%) Grade 1 Gr
Slide 16: Phase 3 VERITAC-2 Trial
San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at SHurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 16 aRate of confirmed complete response or partial response or
Slide 17: Conclusions
17 John G. Houston, Ph.D. President and Chief Executive Officer, Arvinas Conclusions
Slide 18: Continued efficacy and favorable tolerability put ARV-471 on a path to two pivotal studies
Continued efficacy and favorable tolerability put ARV-471 on a path to two pivotal studies beginning soon 18 • Favorable tolerability profile at 200 and 500 mg qd • At 200 mg phase 3 dose, no dose reductions and one discontinuation • ARV-471’s tolerability is well suited for development across the d
Slide 19: VERITAC data confirm ARV-471 has the potential to be a best-in-class ER-targeting therapy
VERITAC data confirm ARV-471 has the potential to be a best-in- class ER-targeting therapy 19 ✓c ✓c ✓c ✓c ✓c ✓c 2020: Phase 1 PoC 2021: Phase 1 Readout 2022: Phase 2 Readout 2022: Planned initiation of TACTIVE-U, TACTIVE-E 2022: Planned initiation of TACTIVE-N 2022: Initiate Phase 1 in Japanese pati
Slide 20: Q&A
Q&A 20